 Adrenal ovarian steroid hormone gonadotropin-releasing hormone agonist treatment polycystic ovary syndrome polycystic ovary syndrome ovarian steroids adrenal steroidogenesis hypothesis basal dexamethasone-suppressed-corticotropin-stimulated steroid hormone responses groups women gonadotropin-releasing hormone agonist treatment months groups women polycystic ovary syndrome high dehydroepiandrosterone sulfate levels micrograms/dl women polycystic ovary syndrome normal dehydroepiandrosterone sulfate levels micrograms/dl normal ovulatory women response gonadotropin-releasing hormone agonist basal serum hormone follicle-stimulating hormone estradiol estrone androstenedione testosterone groups similar levels Basal dehydroepiandrosterone sulfate levels group high levels normal unaltered concentrations groups subjects polycystic ovary syndrome group high levels declines basal serum dehydroepiandrosterone sulfate levels evidence beta-hydroxysteroid dehydrogenase deficiency treatment end treatment groups polycystic ovary syndrome increase maximum incremental rise dehydroepiandrosterone dehydroepiandrosterone sulfate levels response pharmacologic dose corticotropin dexamethasone-suppressed baseline adrenal androgen capacity unaltered gonadotropin-releasing hormone agonist administration ovarian steroids excessive adrenal androgen secretion women polycystic ovary syndrome beta-hydroxysteroid dehydrogenase deficiency mechanism adrenal involvement women polycystic ovary syndrome adrenal androgen capacity